Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.
Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.
Ladone Mary Kay reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Mary Kay Ladone received a grant of 28,081 shares of common stock through a restricted stock unit award. After this compensation grant, she directly holds 104,966 shares. The RSUs will vest on the earlier of one year from grant or the day before the next annual stockholders meeting, assuming she continues in service.
King Kevin M reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Kevin M. King received a grant of 28,081 shares of common stock through a restricted stock unit award. The award was made at no cash cost per share and is a form of equity compensation rather than an open-market purchase.
Following this grant, King directly holds 104,966 shares of Inogen common stock. According to the award terms, the restricted stock units will vest if he continues serving the company until the earlier of one year from the grant date or the day before the next annual stockholder meeting.
Inogen Inc director Jamali Vafa has filed an initial statement of ownership showing a direct holding of 15,000 shares of Common Stock. This Form 3 indicates Vafa’s beneficial ownership position as of the reporting date, with no buy or sell transactions reported in this filing.
Inogen Inc executive Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief Human Resources Officer, reported an open-market sale of 10,770 shares of common stock on May 29, 2026. The shares were sold at a weighted average price of $6.5286, within a price range of $6.41 to $6.62.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following this sale, she directly holds 15,977 shares of Inogen common stock.
Inogen, Inc. reported total revenue of $85.1 million for the quarter ended March 31, 2026, up 3.4% from $82.3 million a year earlier. Sales revenue rose to $72.4 million, driven mainly by stronger international demand, while rental revenue declined to $12.7 million due to fewer patients on service.
Gross margin held roughly steady at 44.5%, but operating expenses increased across research and development, sales and marketing, and general and administrative, leading to a larger net loss of $8.3 million, or $0.30 per share. Inogen ended the quarter with $93.1 million in cash and cash equivalents and used $6.7 million in operating cash. The company also began a share repurchase program, buying back 298,100 shares for about $1.9 million.
Inogen, Inc. reported first quarter 2026 revenue of $85.1 million, up 3.4% from a year earlier, driven by higher international portable oxygen concentrator demand and favorable foreign exchange, which offset lower U.S. sales and rentals. Total gross margin edged up to 44.5%, and adjusted gross margin reached 44.7%.
The company posted a GAAP net loss of $8.3 million (basic and diluted loss of $0.30 per share) versus a $6.2 million loss last year, while adjusted net loss widened to $4.0 million. Adjusted EBITDA was a loss of $1.4 million compared with slightly positive $0.04 million, reflecting increased research and development investments.
Inogen ended the quarter with $111.5 million in cash, cash equivalents, marketable securities, and restricted cash and no debt, and repurchased 298,100 shares for $1.9 million under a $30.0 million authorization. The company guided second quarter 2026 revenue to $94–$97 million and reiterated full-year 2026 revenue of $366–$373 million, about 6.0% growth at the midpoint, and remains focused on improving adjusted EBITDA.
Inogen, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 5, 2026, with a record date of April 6, 2026 covering 27,324,616 shares of common stock.
Key proposals include electing two Class III directors, ratifying Deloitte & Touche as auditor, an advisory say‑on‑pay vote, approving an Amended and Restated 2023 Equity Incentive Plan, and amending the Charter to declassify the Board. The company highlights a strategic turnaround that returned it to positive Adjusted EBITDA in 2025, refreshed leadership with a new independent director and key executives, and a Board-approved share repurchase program. It also emphasizes active stockholder engagement, including a Cooperation Agreement with certain investors and a Board governance change to move from a classified to a declassified structure.
Inogen, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held June 5, 2026 at 1:00 p.m. Eastern Time. The Board asks holders of the 27,324,616 shares outstanding as of April 6, 2026 to vote on five proposals, including director elections, ratification of Deloitte & Touche LLP, advisory approval of executive compensation, approval of an amended and restated 2023 Equity Incentive Plan, and an amendment to the Charter to declassify the Board.
The proxy highlights a recent operational turnaround with a return to positive Adjusted EBITDA in 2025, a Board-approved share repurchase program, the recent appointment of an independent director Vafa Jamali effective the earlier of the Annual Meeting or June 15, 2026, and a Cooperation Agreement with certain investor parties that includes customary standstill provisions and a 4.99% beneficial ownership limit during its term.